UCBJY UCB S.A. UNSP ADR EACH REPR 0.5 ORD
- 65.775
- -0.365-0.55%
- 65.775
- 0.0000.00%
UCB S.A. UNSP ADR EACH REPR 0.5 ORD News
UCB SA's Dividend Analysis
UCB S.A. UNSP ADR EACH REPR 0.5 ORD To Go Ex-Dividend On April 26th, 2024 With 0.72481 USD Dividend Per Share
April 19th - $UCB S.A. UNSP ADR EACH REPR 0.5 ORD(UCBJY.US)$ is trading ex-dividend on April 26th, 2024. Shareholders of record on April 29th, 2024 will receive 0.72481 USD dividend per share on M
Ariceum Therapeutics to Present New Radioligand Therapy Data at American Association for Cancer Research (AACR) Annual Meeting 2024
BERLIN, April 4, 2024 /PRNewswire/ -- Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancer
There's Optimism Around Longboard Pharmaceuticals' Anti-Seizure Candidate: Analyst Boosts Price Target
Tuesday, Longboard Pharmaceuticals Inc (NASDAQ:LBPH) released topline data from the PACIFIC Phase 1b/2a study evaluating bexicaserin (LP352) for seizures associated with a broad range of Developmental
Drugmakers Reportedly Planning to Raise Prices on 500+ Drugs in January
FDA's New Drug Approvals for 2023 Rise 51% From Last Year
FDA Approves UCB's Bimzelx for Plaque Psoriasis
UCB Presents Late-breaking Posters at Child Neurology Society Meeting
ATLANTA, Oct. 4, 2023 /PRNewswire/ -- The Child Neurology Society Meeting, a prominent event in the field of pediatric neurology, is set to showcase cutting-edge research and developments in child neurology. As part of
Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst
Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ:DNTH), a recent reverse merger with the old Magenta Therapeutics. The analysts initiate with an Outperform rating and a price targ
EMA Advisors Recommend Many New Meds at Latest Meeting
Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Asserts
Needham initiated coverage on MoonLake Immunotherapeutics (NASDAQ:MLTX) with a Buy rating and a price target of $76. The analysts Serge Belanger and Rohit Bhasin note the company's lead product devel
Crohn's Disease Drugmakers Set to Benefit From Expected Rise in Cases
UCB Announces U.S. Availability of RYSTIGGO (Rozanolixizumab-noli) for the Treatment of Generalized Myasthenia Gravis (GMG) in Adult Patients Who Are Anti-acetylcholine Receptor (AChR) or Anti-muscle-specific Tyrosine Kinase (MuSK) Antibody Positive.
RYSTIGGO is now commercially available by prescription in the United States for adult patients with gMG who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive1RYSTIGGO
FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults
The FDA approved UCB SA's (OTC:UCBJF) (OTC:UCBJY) Rystiggo (rozanolixizumab-noli) for generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or anti-muscle-sp
UCB Announces U.S. FDA Approval of RYSTIGGO (Rozanolixizumab-noli) for the Treatment of Adults With Generalized Myasthenia Gravis
FDA approval of RYSTIGGO (rozanolixizumab-noli) has been granted under the Priority Review designation for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor
ClearPoint Neuro in Pact With UCB for Gene Therapy Delivery
Veeva in Pact With Belgian Biopharma UCB for Tech-driven Clinical Trials
MoonLake Immunotherapeutics a New Buy at Guggenheim on Sonelokimab
UCB S.A. UNSP ADR EACH REPR 0.5 ORD To Go Ex-Dividend On May 1st, 2023 With 0.72611 USD Dividend Per Share
April 28th - $UCB S.A. UNSP ADR EACH REPR 0.5 ORD(UCBJY.US)$ is trading ex-dividend on May 1st, 2023. Shareholders of record on May 2nd, 2023 will receive 0.72611 USD dividend per share on May 18t
MoonLake Rises 11% as Wedbush Adds to Best Ideas List
Analysis
Price Target
No Data
